Previous 10 | Next 10 |
SANTA MONICA, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended March ...
SANTA MONICA, Calif., April 28, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that it will report its financial results for the fir...
SANTA MONICA, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that it will report its financial results for the four...
Opiant Pharmaceuticals (NASDAQ: OPNT ) has signed a Letter of Intent with NIH's National Center for Advancing Translational Sciences (NCATS) to collaborate on the development of OPNT004 (drinabant) for the treatment of acute cannabinoid overdose (ACO). More news on: Opiant Pharmaceutical...
SANTA MONICA, Calif., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that it has signed a Letter of Intent with the Na...
U.S. Health and Human Services unit BARDA has awarded the second tranche of its contract with Opiant Pharmaceuticals (NASDAQ: OPNT ), valued at ~$2.4M, to accelerate the development of nasal nalmefene for the potential treatment of opioid overdose. More news on: Opiant Pharmaceuticals, I...
SANTA MONICA, Calif., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that it has been awarded the second tranche of ap...
Ultra-thinly traded nano cap BioCorRx ( OTCQB:BICX +7.7% ) is up, albeit on only 700 shares, in reaction to encouraging preclinical data on VDM-001, its candidate for the reversal of opioid overdose that it says is an alternative to naloxone. More news on: BioCorRx Inc., Aurobindo Phar...
Opiant Pharmaceuticals, Inc. (OPNT) Q3 2019 Earnings Conference Call November 12, 2019, 04:30 PM ET Company Participants Rahsaan Thompson - General Counsel Roger Crystal - CEO David O'Toole - CFO Conference Call Participants David Bautz - Zacks Presentation Operator...
Opiant Pharmaceuticals (NASDAQ: OPNT ): Q3 GAAP EPS of $1.97 beats by $2.10 . Revenue of $20.64M (+372.3% Y/Y) beats by $15.12M . Press Release More news on: Opiant Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,
News, Short Squeeze, Breakout and More Instantly...
Opiant Pharmaceuticals Inc. Company Name:
OPNT Stock Symbol:
NASDAQ Market:
CFIUS clearance represents the final required regulatory approval to complete the proposed merger Completion remains subject to the approval of Opiant stockholders; a special stockholder meeting to approve the acquisition will be held on March 1, 2023 Indivior and Opiant c...
SANTA MONICA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) announced today the expiration of the waiting period under the United States (U.S.) Hart-Scott-Rodino Act of 1976, as amended (HSR Act), with respect to the previously announced agreement for Opiant...
FDA sets PDUFA date of May 22, 2023 SANTA MONICA, Calif., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for...